Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Risks Becoming ‘Economically Unviable’ For Biosimilars

BGMA Report Warns Over VPAS Impact And Calls For National Biosimilars Strategy

Executive Summary

Amid increasing financial pressure from the VPAS rebate scheme and a lack of a national uptake strategy, the BGMA has warned that the UK risks losing its leading position in European biosimilars and could become altogether “economically unviable” for biosimilars suppliers.

You may also be interested in...

BGMA Welcomes ‘Differentiated’ Approach To UK Statutory Scheme

Proposals published by the UK government as part of a consultation on its statutory scheme for branded medicine pricing have been welcomed by local off-patent industry association the BGMA. The proposals include a “lifecycle adjustment” mechanism to allow a lower rebate rate for medicines being sold in competitive markets.

BGMA Sets Out Suggestions For VPAS Overhaul

Claiming that the UK’s VPAS rebate scheme is “out of control,” local generics and biosimilars association the BGMA has set out a series of suggestions to improve the mechanism, as it continues to battle for formal involvement in negotiations with the government.

Latest UK Rebate Rate Pushes Profit Out Of Portfolios

The UK government’s announcement of a 26.5% VPAS rate for 2023 “will make some products lossmaking,” the BGMA has cautioned, expressing serious concerns for the branded generics and biosimilars sector as it points to the risk of shortages, higher prices and fewer launches in the UK.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts